The first medical device using artificial intelligence to detect mild or sever levels of diabetic retinopathy in adults with diabetes has been permitted by the US FDA. This decision permits the marketing of this artificial intelligence based novel technology which can be used in a primary care doctors office. This device is named as IDx-DR, which is a software programme that uses an Al algorithm and analyzes the eye images with a retinal camera called Topcon NW400. These digital images are then uploaded to a cloud server on which the IDx-DR software is installed.
Based on the image the software gives the doctor one of the two results, either more than mild diabetic retinopathy or a negative to more than mild diabetic retinopathy. This is the first device which is authorized for marketing which provides a decision without the need of clinician. It can be very useful and can be used by…
